ArsenalBio, a well-funded cell therapy startup, halves workforce to focus...
Arsenal Biosciences is letting go of half of its staff, CEO Ken Drazan confirmed to Endpoints News. The major staffing cuts come almost a year to the day after the clinical-stage cell therapy maker ...
View ArticleA new use for a very old drug: Aspirin cut risk of recurrence for some types...
For colorectal cancer patients with specific tumor mutations, taking an aspirin pill every day could substantially lower the odds of their disease coming back after surgery. While aspirin use has been...
View Article#EASD25: Lilly seeks Mounjaro approval for children with diabetes following...
VIENNA — Eli Lilly said Wednesday it had filed for approval of its diabetes drug Mounjaro in children after a Phase 3 trial showed that the shot cut blood sugar and body weight in patients as ...
View ArticleRoche to enter FGF21 space with $2.4B buyout of MASH biotech 89bio
In its first acquisition of the year, Roche said it is spending $2.4 billion to buy 89bio and its late-stage candidate for fatty liver disease, marking the Swiss drugmaker’s latest bid to boost its...
View ArticleA Blue Shield of California spinout aims to upgrade health plan's tech
Stellarus, a health tech spinout from Blue Shield of California, intends to deploy its technology that powers the insurer — starting with two other Blues plans. In January, Blue Shield of California...
View ArticleLife sciences VC firm, with Bob Langer as chair, closes $77M inaugural fund
A new life sciences VC firm officially launched on Thursday morning, a rarity in today's funding environment. Much of the money being pumped into life sciences venture funds in recent years has gone to...
View ArticleAcadia delays UK drug launch plans due to high market entry barrier for biotechs
Acadia Pharmaceuticals' plans to seek UK approval for its Rett syndrome drug Daybue are "postponed indefinitely" due to high taxes and reimbursement challenges in the country, CEO Catherine Adams told...
View ArticleLeadership changes at Avid Bio and Charles River; Merck KGaA opens €150M...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Charles River Laboratories CFO Flavia Pease is stepping down after...
View ArticleSome ACIP members flag access issues before vote on MMRV shot
Two of the CDC’s vaccine advisors raised questions about access ahead of a vote on whether to stop recommending the combined MMRV shot for kids under the age of 4. The Advisory Committee on...
View ArticleShape Therapeutics strikes AAV capsid deal with VectorY worth up to $1.2B
Shape Therapeutics has forged a major partnership months after letting go of a sizable portion of its workforce as it searches for a permanent CEO. The Seattle RNA gene therapy startup will team up...
View ArticlePfizer, Arvinas to sell rights to lead PROTAC one month after filing for FDA...
Pfizer and Arvinas decided to out-license the lead program in their PROTAC collaboration after it fell short of expectations in late-stage clinical trials earlier this year. The companies said...
View ArticleNektar’s stock rallies on eczema data; Novo to lay off 263 workers in NJ
Plus, news about Bristol Myers Squibb, Nanobiotix, Biogen, bluebird bio, Kairos, BioCardia and Immuto Scientific: 🧪 Nektar Therapeutics’ full Phase 2b eczema data: The company said rezpegaldesleukin,...
View ArticleLogistics real estate company Prologis promises £3.9B in UK life sciences...
The real estate and logistics investment trust Prologis will invest £3.9 billion to boost life science manufacturing and create jobs in the UK. The pledge will focus on expanding manufacturing at the...
View ArticleTelehealth advertising comes under FDA scrutiny
Well, it finally happened. This week, the FDA posted warning letters it sent to telehealth companies that are selling compounded GLP-1 medications, including Hims & Hers and Remedy Meds. The ...
View ArticleReplimune's stock sinks on rocky path forward for cancer treatment
Replimune's shares fell by more than 40% on Thursday after the Massachusetts-based company raised fresh questions about the path forward for its melanoma drug under the FDA's accelerated approval...
View ArticleRare pediatric voucher reauthorization again advances out of House committee
For the second time in two years, the House Committee on Energy and Commerce advanced a bill that would restart the rare pediatric priority review voucher (PRV) program. The FDA program, created in...
View ArticleFDA rescinds lab-developed test rule after court order
The FDA is officially reversing a rule that brought laboratory-developed tests under the agency’s regulation. The move is a formality after a federal district court in Texas struck down the rule in ...
View ArticleLaura Shawver finds her next big bet; Sangamo CFO hands in resignation
→ Laura Shawver likes AbbVie. The longtime industry stalwart is the new board chair at RNA medicines startup ADARx Pharmaceuticals. Shawver replaces
View ArticleRegeneron posts update on its muscle-sparing approach, a new quadruple...
VIENNA — Eli Lilly was undoubtedly the star of this year’s congress of the European Association for the Study of Diabetes. Despite being slightly less effective than Novo Nordisk’s rival pill, Lilly's...
View ArticleEndpoints 11 winner 2025: Lila Sciences will let 'scientific...
Lila Sciences launched this March with ...
View Article